As per last concall, the USFDA approvals would need upto 15/20cr. Clinical trials itself cost 2 mil. This would be needed over the period of 2 yrs. My guess is that the additional money would be for acquisition. Let’s hear that from management during concall whenever it gets scheduled.
I do have following additional questions, putting it across so that we can collaborate and ask questions whoever gets opportunity during con call.
- What do we plan to do with additional capital being raised?
- What is the progress on registration process with USFDA?
- B2C – what is the progress, when can we start recognizing sales. What is overall strategy, branding, distribution plan etc
- On Govt of South Africa order, how much of that is now remaining to be delivered in Q4 & fy18?
- Regarding repeat order from Govt of South Africa, we had following update from earlier conf call.
We have several round of meeting. Their deadline is Dec 17. June 18 is current tender. They may increase by 40% more.
any further update on it? - During Jan to mar we expect more tenders to come out which would be for fy18/fy19. How is the tender pipeline looking and anything that we are winning from it?
Disc: Invested